Ishida, Junichi

[["dc.bibliographiccitation.firstpage","233"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","234"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:14:37Z"],["dc.date.available","2018-11-07T10:14:37Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1002/jcsm.12119"],["dc.identifier.isi","000378159000013"],["dc.identifier.pmid","27493876"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13306"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40651"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The concept that focuses on oral motor and feeding function in cancer patients with muscle wasting"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","394"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.bibliographiccitation.lastpage","395"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-09T11:42:33Z"],["dc.date.available","2019-07-09T11:42:33Z"],["dc.date.issued","2015-12-01"],["dc.description.abstract","not available"],["dc.identifier.doi","10.1002/jcsm.12081"],["dc.identifier.pmid","26674583"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13565"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58692"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Concern regarding quality and quality of muscle."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-09T11:43:39Z"],["dc.date.available","2019-07-09T11:43:39Z"],["dc.date.issued","2017-08-31"],["dc.identifier.doi","10.1002/jcsm.12230"],["dc.identifier.pmid","28857511"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14612"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58937"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Considering technique of assessment and method for normalizing skeletal muscle mass."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","37"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","42"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:22:26Z"],["dc.date.available","2018-11-07T10:22:26Z"],["dc.date.issued","2017"],["dc.description.abstract","Background: Myostatin, a negative regulator of skeletal muscle mass, is up-regulated in the myocardiumof heart failure (HF) and increasedmyostatin is associatedwithweight loss in animal models with HF. Although there are disparities in pathophysiology and epidemiology between male and female patients with HF, it remains unclear whether there is gender difference in myostatin expression and whether it is associated with weight loss in HF patients. Methods: Heart tissue sampleswere collected frompatientswith advanced heart failure (n= 31, female n= 5) as well as healthy control donors (n= 14, female n= 6). Expression levels of myostatin and its related proteins in the heart were evaluated by western blotting analysis. Results: Body mass index was significantly lower in female HF patients than inmale counterparts (20.0 +/- 4.2 in female vs 25.2 +/- 3.8 in male, p= 0.04). In female HF patients, both mature myostatin and pSmad2 were significantly up-regulated by 1.9 fold (p= 0.05) and 2.5 fold (p < 0.01) respectively compared to female donors, while expression of pSmad2was increased by 2.8 times inmale HF patients compared to male healthy subjects, but that of myostatinwas not. Therewas no significant difference in protein expression related tomyostatin signaling between male and female patients. Conclusion: In this study, myostatin and pSmad2 were significantly up-regulated in the failing heart of female patients, but notmale patients, and female patients displayed lower body mass index. Enhancedmyostatin signaling in female failing heart may causally contribute to pathogenesis of HF and cardiac cachexia. (C) 2017 Elsevier B. V. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2017.03.153"],["dc.identifier.isi","000402478900007"],["dc.identifier.pmid","28465115"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42273"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Myostatin signaling is up-regulated in female patients with advanced heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","12"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","18"],["dc.bibliographiccitation.volume","238"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T10:22:25Z"],["dc.date.available","2018-11-07T10:22:25Z"],["dc.date.issued","2017"],["dc.description.abstract","Cachexia is defined as a complex metabolic syndrome associated with underlying illness that is characterized by the loss of body weight consisting of muscle and fat mass wasting. Sarcopenia is defined as the ageing related loss of muscle mass in health and disease that may not have an effect on body weight. As millions of patients are in cachectic or sarcopenic states, both conditions contribute to high numbers to death worldwide. A number of treatments have been proposed for cachexia and sarcopenia, but these are either in the preclinical stage or in clinical trials and hence not available to the general population. Particularly in cachexia there is a massive problem of recruiting patients for trials and also with the follow-up, due to the seriousness of the disease. This underlines the importance of well-characterized animal models. Obviously, most of the widely used cachexia and sarcopenia animal models have limitations in reproducibility of the condition and novel models are warranted in this context. The key findings of developing models in the field of cachexia and sarcopenia are that more types of the conditions have been taken into the researchers' interest. In cardiac cachexia, technical issues, which limit the preciseness and reproducibility in surgical heart failure models, have been overcome by a combination of surgery and the use of transgenic mouse models or salt sensitive rat models. Fatigue is the most pronounced symptom of cachexia and may be caused by reduced cardiac function independent of the underlying disease. Sarcopenia models often suffer from the use of young animals, due to the limited availability and very high costs of using aged animals. This review will focus on rodent models designed to mimic cachexia and sarcopenia including co-morbidities such as cancer, heart failure, as well as other diseases and conditions. (C) 2017 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2017.03.154"],["dc.identifier.isi","000402478900003"],["dc.identifier.pmid","28476513"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42270"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Animal models of cachexia and sarcopenia in chronic illness: Cardiac function, body composition changes and therapeutic results"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","515"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","519"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2018-11-07T10:05:27Z"],["dc.date.available","2018-11-07T10:05:27Z"],["dc.date.issued","2016"],["dc.description.abstract","Even though most clinical data on cachexia have been reported from Western countries, cachexia may be a growing problem in Asia as well, as the population in this area of the world is considerably larger. Considering the current definitions of obesity and sarcopenia in Japan, which are different from the ones in Western countries, the lack of a distinct cachexia definition in Japan is strinking. Only one epidemiological study has reported the prevalence of cachexia using weight loss as part of the definition in patients with stage III or IV non-small cell lung cancer. Although the reported prevalence of 45.6% is within the range of that in Western countries (28-57% in advanced cancer), we cannot compare the prevalence of cachexia in other types of cancer, heart failure, chronic obstructive pulmonary disease (COPD), and kidney disease (CKD) between Japan and Western countries. In patients with heart failure, one third of Japanese patients has a body mass index <20.3kg/m(2) whereas the prevalence of underweight is 13.6% in reports from Western countries. These results may suggest that there are more cachectic heart failure patients in Japan, or that using the same definition like Western countries leads to gross overestimation of the prevalence of cachexia in Japan. The rate of underweight patients in COPD has been reported as 31-41% in COPD and seems to be high in comparison to the prevalence of cachexia in Western countries (27-35%). The reported lowest quartile value of BMI (19.6 kg/m(2)) in CKD may match with the prevalence of cachexia in Western countries (30-60%). The number of clinical trials targeting cachexia is very limited in Japan so far."],["dc.identifier.doi","10.1002/jcsm.12117"],["dc.identifier.isi","000388495400004"],["dc.identifier.pmid","27239422"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13985"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38895"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","393"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.bibliographiccitation.lastpage","393"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Hatanaka, Michiyoshi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Ishida, Junnichi"],["dc.contributor.author","Saito, Masakazu"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-09T11:42:34Z"],["dc.date.available","2019-07-09T11:42:34Z"],["dc.date.issued","2015-12-01"],["dc.description.abstract","not available"],["dc.identifier.doi","10.1002/jcsm.12084"],["dc.identifier.pmid","26674390"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13570"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58695"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Novel mechanism of ghrelin therapy for cachexia."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.volume","247"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2020-12-10T14:24:31Z"],["dc.date.available","2020-12-10T14:24:31Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1016/j.ijcard.2017.06.094"],["dc.identifier.issn","0167-5273"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72275"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Reply to letter to the editor “suramin against myostatin signaling may be considered to intervene in female patients with advanced heart failure”"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","392"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Konishi, Masaaki"],["dc.contributor.author","Saito, Masakazu"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2018-11-07T09:48:30Z"],["dc.date.available","2018-11-07T09:48:30Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1002/jcsm.12080"],["dc.identifier.isi","000365536800017"],["dc.identifier.pmid","26674220"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35320"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.title","Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Haehling, Stephan von"],["dc.date.accessioned","2019-07-15T10:49:08Z"],["dc.date.available","2019-07-15T10:49:08Z"],["dc.date.issued","2019"],["dc.description.abstract","Growth hormone secretagogues (GHSs) are a generic term to describe compounds which increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS‐R), whose natural ligand is ghrelin, and agonists of the growth hormone‐releasing hormone receptor (GHRH‐R), to which the growth hormonereleasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosisg of GH deficiency, which causes growth retardation, gastrointestinal dysfunction and altered body composition, in parallel with extensive research to identify GHRH, GHS‐R and ghrelin. This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials. Furthermore, we will highlight the publicly disclosed clinical trials regarding GHSs."],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16281"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61499"],["dc.language.iso","en"],["dc.title","Growth hormone secretagogues: history, mechanism of action and clinical development"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]